Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice.
Ca2+ oscillation
NF-κB
evodiamine
osteoclast
osteoporosis
ovariectomy
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
21
07
2018
accepted:
14
09
2018
pubmed:
20
11
2018
medline:
20
11
2018
entrez:
20
11
2018
Statut:
ppublish
Résumé
Postmenopausal osteoporosis (PMO) is a progressive bone disease characterized by the over-production and activation of osteoclasts in elderly women. In our study, we investigated the anti-osteoclastogenic effect of evodiamine (EVO) in vivo and in vitro, as well as the underlying mechanism. By using an in vitro bone marrow macrophage (BMM)-derived osteoclast culture system, we found that EVO inhibited osteoclast formation, hydroxyapatite resorption and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene and protein expression. Mechanistically, we found that EVO inhibited the degradation and RANKL-induced transcriptional activity of IκBα. RANKL-induced Ca
Identifiants
pubmed: 30451360
doi: 10.1111/jcmm.13955
pmc: PMC6307789
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
522-534Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Références
Nature. 2003 May 15;423(6937):337-42
pubmed: 12748652
Bone. 2008 Jul;43(1):92-100
pubmed: 18407820
Neurochem Res. 2014 Aug;39(8):1612-20
pubmed: 24919817
Planta Med. 2013 Jan;79(1):27-9
pubmed: 23161424
J Nat Prod. 2007 Mar;70(3):461-77
pubmed: 17309302
Acta Reumatol Port. 2007 Apr-Jun;32(2):103-10
pubmed: 17572649
Immunol Rev. 2009 Sep;231(1):241-56
pubmed: 19754901
J Pathol. 2000 Sep;192(1):4-13
pubmed: 10951393
Science. 1994 Oct 21;266(5184):443-8
pubmed: 7939685
J Biol Chem. 2009 May 22;284(21):14667-76
pubmed: 19321441
EMBO J. 2001 Mar 15;20(6):1271-80
pubmed: 11250893
Molecules. 2009 May 18;14(5):1852-9
pubmed: 19471205
J Bone Metab. 2014 Feb;21(1):21-8
pubmed: 24707464
Front Biosci. 2007 Jan 01;12:2519-29
pubmed: 17127260
J Clin Densitom. 2013 Oct-Dec;16(4):445-9
pubmed: 24090647
Proc Am Thorac Soc. 2005;2(4):386-90; discussion 394-5
pubmed: 16267367
Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8643-8
pubmed: 18552177
Shock. 2009 Sep;32(3):263-9
pubmed: 19106818
Metabolism. 1999 Dec;48(12):1532-5
pubmed: 10599984
J Mol Med (Berl). 2005 Mar;83(3):170-9
pubmed: 15776286
Biochem J. 2013 Apr 15;451(2):235-44
pubmed: 23379601
J Bone Miner Res. 2000 Nov;15(11):2178-86
pubmed: 11092398
Ann N Y Acad Sci. 2007 Nov;1116:227-37
pubmed: 18083930
J Bone Miner Res. 2003 Dec;18(12):2159-68
pubmed: 14672351
Mayo Clin Proc. 2009 Jul;84(7):632-7; quiz 638
pubmed: 19567717
Lancet. 2011 Apr 9;377(9773):1276-87
pubmed: 21450337
Bone. 2007 Feb;40(2):251-64
pubmed: 17098490
J Exp Med. 2005 Nov 7;202(9):1261-9
pubmed: 16275763
Arch Pharm Res. 2006 Apr;29(4):293-7
pubmed: 16681034
Swiss Med Wkly. 2012 Jul 19;142:w13624
pubmed: 22815185
J Cell Mol Med. 2019 Jan;23(1):522-534
pubmed: 30451360
J Clin Invest. 2008 Nov;118(11):3775-89
pubmed: 18846253